Drug development

#Covid-19 #Drug development #Drug discovery #Drug targets

Targeted treatments for respiratory infections

A new experimental model that more accurately replicates the impact of respiratory infections on the lungs and upper airways has been developed through an SME and academic partnership supported by the Infection Innovation Consortium (iiCON). Led by Founding Director, Professor Janet Hemingway CBE of Liverpool School of Tropical Medicine, iiCON… Read More

#News

#Covid-19 #Drug development #Drug discovery #mRNA

Can antiviral oligonucleotides better prepare us for the next pandemic?

Todd Stawicki, Global Marketing Manager for MS Biopharma at SCIEX, offers an in-depth analysis of oligonucleotides and their role in preparing for the next pandemic Covid-19, the disease caused by SARS-CoV-2, is arguably the greatest public health threat in a generation. It has temporarily paralysed our just-in-time economy1,2 and highlighted many… Read More

#Exclusive Content #News

#Drug delivery #Drug development #mRNA #Pfizer

Pfizer’s investment that will help speed up new medicine development

Around 85% of Pfizer's small molecule products pass through Sandwich, Kent, on their journey to market. The work of the Kent site’s team helps millions of patients globally. Brian Henry, Vice President, Drug Product Design, Medicinal Sciences provides Megan Thomas, Drug Discovery World with insight into the scientific learnings of… Read More

#Exclusive Content #News

#Clinical trials #Drug development #Drug discovery

163% growth in recruiting clinical trial sites in China

Virtual clinical development specialist Phesi has released its analysis of the growth in recruiting clinical trial sites in China since the beginning of 2018. The analysis finds a significant rise in the number of recruiting sites in the country, with a 163% increase between January 2018 and January 2021. While… Read More

#News

#Cancer research #CAR-T #Cell therapy #Drug development #Immuno-oncology

Innovation driving cell therapies toward the clinic

Sean Chang, Product Manager, Cell and Gene Therapy at Thermo Fisher Scientific It has been four years since the first Chimeric Antigen Receptor T-cell (CAR T) therapy drug, Kymriah1, was approved by the US Food and Drug Administration (FDA) for the treatment of B-cell acute lymphoblastic leukaemia (ALL). Since then,… Read More

#Exclusive Content #News

Eye
#Biotechnology #Clinical trials #Drug development #Drug discovery #Stem cells

Dry Eye Syndrome drug candidate shows promise

BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the… Read More

#News

#Antibodies #Complex medicines #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug targets #Life sciences

Financial benefit of complex medicines to UK life sciences

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK… Read More

#News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Sanofi launches dedicated mRNA vaccines centre

Sanofi will invest approximately €400 million annually in a vaccines mRNA Centre of Excellence. The centre will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams… Read More

#News

#Cancer research #Drug development #Drug discovery #Drug innovation #Oncology #Research #Therapeutics

Sitting down with… Mari Scheiffele, Novartis

Mari Scheiffele is the General Manager for Oncology in the UK & Ireland at Novartis, responsible for launching innovative oncology therapies that can help to change the lives of people living with different types of cancer. She speaks to Lu Rahman about her passion for working with her teams to… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#AI #Drug development #Drug discovery #Novel candidates #Therapeutics

Strategic collaboration could open the door to new world-class medicines

EQRx and Exscientia are collaborating to combine the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates and expand EQRx’s pipeline of novel therapies. This collaboration is focused on creating improvements in the traditional drug discovery and development processes by improving the probability of success… Read More

#News

#Biotherapeutics #Cancer research #CAR-T #Cell therapy #Clinical trials #Drug development

Aleta and Cancer Research UK to advance blood cancer therapy

Aleta Biotherapeutics and Cancer Research UK have collaborated to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001. Under the terms of the clinical development partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase I/IIa clinical trial of ALETA-001,… Read More

#News

#Antigen #Awards #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Winners of ‘The Best Covid-19 Responder’ announced

The Native Antigen Company has won ‘The Best Covid-19 Responder’ at the OBN 2020 Awards. The award recognises the Company’s contribution to the fight against Covid-19. The Native Antigen Company has utilised its expertise in developing high-quality reagents to play a major role in the global response to SARS-CoV-2. In… Read More

#News

#Automation / robotics #Bioscience #CRO #Drug delivery #Drug development

Video highlights reinvention of western blotting

Aurelia Bioscience, a Nottingham, UK based pre-clinical Contract Research Organisation (CRO) has produced a new video to explain the functioning of WES and JESS – two highly reproducible, capillary based, automated western blot instruments from ProteinSimple: Whilst traditional western blotting typically runs 10-20 samples in three to five… Read More

#News

#AstraZeneca #Biologics / Biotechnology #Clinical trials #Drug delivery #Drug development #Pharma

Chinese/Western partnership to promote indigenous drugs

Chinese biopharma companies are eyeing strategic collaborations with Western counterparts to leverage their networks and commercial capabilities to promote indigenously developed drugs in China, says GlobalData, a data and analytics company. China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with AstraZeneca China in May 2021 regarding the… Read More

#Market Reports #News #Trends & Analysis

#Biologics #Biopharmaceuticals #Drug delivery #Drug development #Events #Process analytical technology

Agilent completes the InfinityLab Bio LC portfolio

Agilent Technologies has launched three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release has been described by Agilent as central to its portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that integrate with Agilent OpenLab and MassHunter software, and… Read More

#News

#Biosciences #Drug delivery #Drug development #Drug discovery

Charnwood Group acquires Aurelia Bioscience

Aurelia Bioscience has announced that after ten years as a standalone biology contract research organisation, the company has been acquired by its collaborator Charnwood Molecular. Co-located in BioCity Nottingham, Aurelia Bioscience and Charnwood Molecular have previously jointly delivered research projects. This acquisition is said to allow both companies to formally… Read More

#News